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Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to joint destruction and disability.
Peroxisome proliferator-activated receptor-gamma coactivator-1beta (PGC-1β) is a transcriptional coactivator that
plays important roles in regulating multiple aspects of energy metabolism and cytokine signaling pathways. PGC-1β
overexpression leads to the attenuation of macrophage-mediated inflammation. In this study, we aimed to determine
the expression of PGC-1β in RA synovium and fibroblast-like synoviocytes (FLS), and explore the mechanisms of
PGC-1β on both the proinflammatory effects and apoptosis in RA-FLS.
Methods: Synovium was obtained from 31 patients with active RA, as well as 13 osteoarthritis (OA) and 10
orthopedic arthropathies (Orth.A) as “less inflamed” disease controls. FLS were then isolated and cultured.
Synovial PGC-1β expression was determined by immunohistochemistry staining, while FLS PGC-1β expression
was detected by immunofluorescence staining, quantitative real-time PCR (qPCR) assay and western blot. PGC-1β
was depleted by lentivirus sh-RNA, and up-regulated by pcDNA3.1- PGC-1β. The expression of proinflammatory
cytokines, matrix metalloproteinases and receptor activator of nuclear factor-kappaB ligand was analyzed by
qPCR, cytometric bead array and western blot. The expression of mitogen-activated protein kinases and nuclear
factor-kappaB (NF-κB) was determined by qPCR and western blot. Besides, cell apoptosis was examined using flow
cytometry. The interaction between PGC-1β and NF-κB was performed by dual-luciferase reporter gene assays.
Results: (A) Synovial PGC-1β was over-expressed in RA patients compared with OA or Orth.A patients. (B) PGC-1β
expression significantly increased in RA-FLS compared with OA-FLS. (C) PGC-1β mediated the expression of
proinflammatory cytokines and apoptosis through extracellular signal-regulated kinase (ERK), p38 and NF-κB in
RA-FLS. (D) PGC-1β mediated NF-κB transcription in RA-FLS, but did not affect ERK and p38.
Conclusion: The results indicate that PGC-1β may play important roles in the proinflammatory effects and
apoptosis of RA-FLS.* Correspondence: liedai2004@163.com
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Rheumatoid arthritis (RA) is a common chronic inflam-
matory disease characterized by chronic inflammatory
synovitis, leading to invasion of synovial tissue into the ad-
jacent cartilage matrix with degradation of articular cartil-
age and bone [1]. RA affects 0.5% to 1.0% of the population
worldwide [2]. During the last few decades, treatment op-
tions have diversified and the availability and selection of
different treatments for individual patients has greatly im-
proved. Despite these advances, a cure for RA is not yet
available. Therefore, the precise etiology and underlying
mechanisms of the condition require further elucidation.
Fibroblast-like synoviocytes (FLS) are recognized as a
prominent joint-specific determinant of RA because of
their hyperproliferative properties and hyperproduction
of both proinflammatory cytokines that perpetuate in-
flammation and matrix metalloproteinases (MMPs) that
contribute to cartilage destruction [3,4]. Briefly, proinflam-
matory cytokines such as TNF-α and IL-1β strongly initiate
FLS, and consistently enhance and potentially stabilize the
activated phenotype of FLS [5]. The activation of FLS can
produce TNF-α, IL-1β and IL-6, all of which are involved
in sustaining regulatory feedback loops and inducing pro-
duction of MMPs, cathepsins and aggrecanases [6]. Acti-
vated FLS can also produce IL-8, which is implicated in
leukocyte recruitment to diseased synovium [7]. FLS gov-
ern the differentiation of macrophages into osteoclasts
through upregulation of receptor activator of nuclear
factor kappa-B ligand (RANKL) [8]. This phenomenon
is coordinated with cellular mitogen-activated protein
kinase (MAPK) and nuclear factor-kappaB (NF-κB) sig-
naling pathways being stimulated. These feedback loops
are regarded as significant regulators of proinflammatory
cytokines in RA [9,10]. As FLS are key effectors in the
pathogenesis of RA, recent approaches for RA treatment
have focused on the inhibition of its function and induc-
tion of cell death, including the modulation of activ-
ities of various nuclear transcriptional factors relevant
to the inflammatory process [11-13].
Peroxisome proliferator-activated receptor-gamma
coactivator-1 (PGC-1) is a transcriptional coactivator
that plays important roles in regulating multiple as-
pects of energy metabolism and cytokine signaling
pathways through interaction with many transcription
factors [14,15]. The first member of the PGC-1 family is
now termed PGC-1α, while PGC-1β is the closest homo-
log of PGC-1α and shares extensive sequence identity
[15,16]. Emerging evidence suggests that PGC-1 plays im-
portant roles in regulating inflammation. PGC-1 can vis-
ibly suppress proinflammatory effects by inhibiting the
activation of NF-κB in skeletal muscle cells [17]. PGC-1α
has been demonstrated to be capable of regulating inflam-
mation by suppressing the expression of TNF-α, IL-6,
IL-8 and IL-1β mRNA levels in human skeletal muscle[18]. Overexpression of PGC-1α decreased both basal and
platelet-derived growth factor-induced p38 MAPK phos-
phorylation [19]. More importantly, increased expression
of PGC-1β resulted in the attenuation of macrophage-
mediated inflammation [20]. PGC-1β is therefore a crit-
ical mediator in regulating proinflammatory cytokines.
However, until now, whether PGC-1β participates in the
pathophysiological development of RA has been poorly
understood. This study aimed to determine the expression
of PGC-1β in RA synovium and FLS, and explore the
mechanisms of PGC-1β on both the proinflammatory ef-
fects and apoptosis in RA-FLS.
Methods and materials
Patients
Thirty-one Chinese patients with RA who fulfilled
the 1987 revised criteria of the American College of
Rheumatology (ACR) [21] or 2010 ACR/European League
against Rheumatism (EULAR) classification criteria
for RA [22] were included from the Department of
Rheumatology of Sun Yat-sen Memorial Hospital. All
patients had active disease, defined as a 28-joint disease
activity score (DAS28) ≥2.6. Thirteen patients with osteo-
arthritis (OA) and ten with non-inflammatory orthopedic
arthropathies (Orth.A), including five with meniscus in-
jury, two with anterior cruciate ligament injuries, one with
traumatic arthritis, one with medial plica syndrome, one
with discoid meniscus, were included from the Depart-
ment of Rheumatology and Orthopedics as less-inflamed
disease controls [23]. Baseline demographic and clinical
features of all patients are shown in Table 1. This study
was conducted in accordance with the Declaration of
Helsinki, and the protocol was approved by Medical
Ethics Committee of Sun Yat-sen Memorial Hospital.
All patients gave written informed consent.
Clinical assessments
Clinical data of all patients with RA were collected at
baseline, including the 28-joint tender and swollen joint
count (28TJC and 28SJC), patient and provider global as-
sessment of disease activity (PtGA and PrGA), pain visual
analog scale (pain VAS), Chinese language version of
Stanford health assessment questionnaire (HAQ) [24],
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP); rheumatoid factor (RF), and anti-cyclic citrulli-
nated peptide antibody (anti-CCP). Disease activity was
assessed with DAS28 with four variables, including CRP
(DAS28 (4)-CRP) [25].
Synovial tissue collection and FLS culture
RA synovium was collected by closed needle biopsy [26].
At least six pieces of synovial tissue were obtained per
patient to minimize sampling error [27]. The OA and
Orth.A specimens were obtained from knees by closed
Table 1 Baseline demographic and clinical features of RA, OA and Orth.A patients in the study of synovial PGC-1β by
immunohistochemistry
Characteristic RA patients (n = 31) OA patients (n = 13) Orth.A patients (n = 10)
Demographic
Age, yrs, median (IQR) 61 (53 to 66) 61 (56 to 65) 32 (25 ~ 44)
Female, n (%) 24 (77.4) 11 (84.6) 5 (50.0)
Disease status
Disease duration, mo, median (IQR) 36 (12 to 120) 60 (24 to 114) 3 (1 to 39)
ESR, mm/h, median (IQR) 82 (50 to 108) 18 (11 to 33) 14 (5 to 38)
CRP, mg/dl, median (IQR) 4.28 (1.89 to 6.05) 0.33 (0.25 to 0.93) 0.19 (0.08 to 0.34)
Rheumatoid factor-positive, n (%) 28 (90.3) NA NA
Anti-CCP-positive, n (%) 26 (83.9) NA NA
DAS28, median (IQR) 5.78 (4.83 to 6.39) NA NA
Previous medications, n (%) NA NA
Corticosteroids 12 (38.7) NA NA
Methotrexate 12 (38.7) NA NA
Leflunomide 5 (16.1) NA NA
Sulfasalazine 1 (3.2) NA NA
Hydroxychloroquine 3 (9.7) NA NA
Etanercept 3 (9.7) NA NA
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, disease activity
score 28-joint assessment; n, number of patients; RA, rheumatoid arthritis; OA, osteoarthritis; Orth.A, orthopedic arthropathies; NA, not applicable.
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were fixed in 10% neutral formalin and embedded in
paraffin. Sections (5 μm) were cut serially and mounted
on adhesive glass slides. Sealed slides were stored at –
20°C until staining.
FLS were isolated from the synovial tissues by modified
tissue culture method [28]. Fresh synovial tissues were
minced and digested in type I collagenase (Sigma-Aldrich,
St Louis, MO, USA). The cells were cultured with
DMEM-Ham’s F-12 (DMEM/F12) (Gibco, Life Tech-
nologies, Shanghai, China), containing 20% fetal calf serum
(Gibco, Life Technologies, Mulgrave, VIC, Australia) in a
humidified 5% CO2 incubator. FLS from passages three to
five were used in this study.
Immunohistochemistry
Serial sections of synovial tissues were stained with H&E
and a three-step immunoperoxidase method for immuno-
histochemistry. Sections were incubated with the PGC-1β
(Bioss, Beijing, China) at 1/200 dilution overnight at 4°C
after deparaffinization and retrieval. The sections were
incubated with EnVision Mouse or Rabbit conjugate
(Dako, Carpinteria, USA) for 30 minutes at 37°C. The
3,3-diaminobenzidine (DAB)-positive substrate was used
for the color reaction. Sections were counterstained with
hematoxylin. Nonspecific isotype IgG was used as a
negative control. The percentage of PGC-1β-positive-
staining cells in the lining layers and sublining areawere determined by manual observation of five differ-
ent fields at magnification × 400, respectively.
Immunofluorescence
FLS were incubated with primary antibody recognizing
PGC-1β (Bioss, Beijing, China) or normal rabbit IgG
(control) after fixation, permeablization and blocking.
FLS were stained with Alexa Fluor 488-conjugated goat
anti-mouse IgG diluted 1:1,000 (Invitrogen, Carlsbad,
USA), and co-stained with 4′6-diamindino-2-phenylindole
(DAPI) (Sigma-Aldrich, St Louis, MO, USA) to visualize
nuclei. FLS were analyzed by confocal microscopy (Zeiss,
Jena, Germany).
Lentivirus infection in RA-FLS
Gene knockdown was performed using lentivirus sh-
RNA, which was synthesized by Shanghai GeneChem Co
Ltd (Shanghai, China). Short hairpin RNA (shRNA) were
cloned into pLKO.1 (GV248) lentiviral vectors. The
sh-PGC-1β targeting sequence was CAGATACACTGA
CTACGAT. Culture supernatants containing sh-RNA
were added to RA-FLS in the presence of polybrene. The
cells were selected using 1 μg/ml puromycin after 24 h.
Stable cell lines were verified by western blot.
Plasmid construction and transfection
The fragment of human PGC-1β was amplified from the
cDNA of 293T cells by using specific primers (forward
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and reverse primer 5′-ATCTCGAGTCAATGCAGGCT
CTGCTG-3′) with the HindIII and XhoI restriction sites.
Following the conditions at 35 cycles at 94°C for 1 minute,
58°C for 180 s, and 72°C for 1 minute, their action was con-
tinued for 10 minutes at 72°C after the last cycle using Ex
Taq Polymerase (Takara, Otsu, Japan). The PCR product
was purified and digested with HindIIIand Xho, then cloned
into a mammalian expression vector pcDNA3.1 (+) with
the corresponding restriction sites (Novagen, Darm-
stad, Germany). The recombinant plasmid was con-
firmed by DNA sequencing. RA-FLS were cultured in
6-well cell culture plates to 80 to 90% confluency and
then subjected to transfection using the lipofectamine
TM 2000 reagent (Life Technologies, Carlsbad, USA) ac-
cording to the manufacturer’s instructions. Cells were
harvested 72 h after transfection.
Apoptosis detection assay and cell cycle analysis
The apoptosis of stably transduced RA-FLS was mea-
sured through detecting APC-conjugated Annexin-V
and 7-AAD by flow cytometry (FCM) (BD PharMingen,
San Diego, USA). For cell cycle analysis, they were fixed
with cold ethanol overnight and then treated with propi-
dium iodide and RNase before fluorescence-activated
cell sorting (FACS) analysis. The cell cycle distribution
was determined using flow cytometry (FCM). Apoptosis
and cell cycle were quantified using FACS and CellQuest
software (BD Biosciences, Mountain View, USA).
Quantitative real-time PCR (qPCR)
Total RNA was prepared from cells using RNAiso Reagent
(Takara, Otsu, Japan). Complementary DNA (cDNA) sam-
ples were synthesized with reverse-transcription kit
(Takara, Otsu, Japan). Amplification of the cDNA was per-
formed using specific oligonucleotide primers (Table 2).Table 2 Primers for quantitative real-time PCR












MMP: matrix metalloproteinase; RANKL, receptor activator of nuclear factor-kappa BThe qPCR was performed using QuantiTeckTM SYBR
Green PCR kit (Takara, Otsu, Japan). The reactions
were initiated with denaturation of cDNA templates at
95°C for 30 s, 95°C for 5 s and 60°C for 30 s and
amplification for 40 to 50 cycles. Samples were run in
triplicate in a Roche LightCycler480 sequence detector
system (Roche, Basel, Switzerland).
Western blot analysis
Protein lysates from cells were subjected to SDS-PAGE
and target proteins were detected with primary anti-
bodies recognizing p-p38, p38, P-extracellular signal-
regulated kinase (P-ERK), ERK, p-JNK, JNK, p-NF-κB p65
(Ser536), NF-κβ p65 and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) (CST, Danvers, Massachusetts,
USA), PGC-1β and RANKL (Epitomics, San Francisco,
USA), MMP-3 and MMP-13 (Abcam, Cambridge, USA)
respectively. After incubation with appropriate horse-
radish peroxidase (HRP)-conjugated secondary antibodies
(EarthOx, Millbrae, California, USA), protein bands were
visualized using enhanced chemiluminescence (Millipore,
Boston, USA) plus western blot detection reagents
followed by exposure to a scanning imager (G:BOX Gel &
Blot Imaging Series from Syngene, Cambridge, UK).
Determination of proinflammatory cytokine levels
Proinflammatory cytokines including IL-8, IL-6, IL-1β, and
TNF-α in the culture supernatants were quantified using
cytometric bead array (CBA) human inflammatory cyto-
kines kit (BD Biosciences, San Jose, USA). The cytokines
were analyzed by standard curves plotted using a four-
parameter logistic curve-fitting model.
Dual-luciferase reporter gene assays
Luciferase reporter construct containing the NF-κB pro-












ligand; ERK, extracellular signal-regulated kinase.
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temporarily transfected with 1 μg of the promoter reporter
plasmid into RA-FLS using the Lipofectamine 2000 (Invi-
trogen, Shanghai, China), while 40 ng of the phRL-TK
plasmid were co-transfected into the cells to verify trans-
fection efficiency. Then, RA-FLS cells were co-transfected
with pcDNA3.1-PGC-1β to increase PGC-1β expression,
and empty vector pcDNA3.1 to keep total DNA concen-
tration constant. After 36 h of transfection, the luciferase
activities were measured on a spectraMax M5 reader
(Molecular Devices, California, USA) using the Dual-
Luciferase Reporter Assay System (Promega, Madison,
USA).
Statistical analysis
Statistical analyses were performed with SPSS 13.0 stat-
istical software (SPSS Inc., Chicago, IL, USA). For cat-
egorical variables, data were presented as frequencies
and percentages. For continuous variables, data were pre-
sented as mean and SD, or median and IQR. Nonpara-
metric tests (Mann-Whitney rank-sum test between two
groups, Kruskal-Wallis one-way analysis of variance on
ranks among three or more groups for continuous vari-
ables) were used to compare the differences in PGC-1β
expression in synovium and FLS. Spearman’s rank order
correlation test was used for assessing the correlation be-
tween PGC1-1β expression in RA-FLS and both clinicalFigure 1 Expression of peroxisome proliferator-activated receptor-ga
rheumatoid arthritis (RA). (A) Intensive synovial PGC-1β expression in syn
synovium of an osteoarthritis (OA) patient. (C) Mild synovial PGC-1β expres
(D) Percentage of lining PGC-1β + cells in RA, OA and Orth.A patients.
median ± IQR. **P <0.01, ***P <0.001.indicators and proinflammatory cytokines. Student’s t-test
was used to assess the differences in proinflammatory cy-
tokines, MMPs and RANKL between the experimental
and control groups. Two tailed P-values <0.05 were con-
sidered statistically significant.
Results
Characteristics of the study patients
Baseline demographic and clinical features of all patients
are shown in Table 1. Age and sex did not differ among the
patients with RA and OA. Among the patients with RA,
45% (14/31) had never taken corticosteroids or disease-
modifying anti-rheumatic drugs (DMARDs). These patients
had taken only Chinese herbal medicine and/or painkillers
to relieve arthralgia. At recruitment, 13% (4/31) had taken
corticosteroids alone. The remaining 42% (13/31) received
treatment with one or more DMARDs, including metho-
trexate, leflunomide, sulfasalazine, hydroxychloroquine, or
etanercept.
Expression of PGC-1β is upregulated in synovium
in RA
PGC-1β expression in RA synovium was observed with in-
tense nuclear staining in lining cells (both macrophage-like
synoviocytes and fibroblast-like synoviocytes) and sublin-
ing inflammatory cells (mostly in lymphocytes and plasma
cells). As shown in Figure 1, the percentage of PGC-1β +mma coactivator-1 β (PGC-1β) is upregulated in synovium in
ovium of a RA patient. (B) Moderate synovial PGC-1β expression in
sion in synovium of an orthopedic arthropathy (Orth.A) patient.
A, B, C: original magnification × 400. The data are represented by
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cantly higher than that in OA (median 69%, IQR 47% to
81%) or in Orth.A (median 63%, IQR 48% to 69%). In the
sublining area, the percentage of PGC-1β + lining cells
(median 90%, IQR 86% to 93%) was significantly higher
than that in OA (median 71%, IQR 60% to 86%) or in
Orth.A (median 60%, IQR 50% to 78%).
PGC-1β is over-expressed in RA-FLS
The expression of PGC-1β mRNA and protein in RA-FLS
was detected from eight RA patients and six OA pa-
tients. Their baseline demographic and clinical features are
shown in Table 3. Immunofluorescence staining showed
higher expression of PGC-1β in RA-FLS compared with
OA-FLS (Figure 2A). The expression of PGC-1β mRNA
and protein in RA-FLS was significantly enhanced com-
pared with OA controls (3.18 ± 1.72 versus 1.17 ± 0.74,
P = 0.019; 0.33 ± 0.17 versus 0.11 ± 0.08, P = 0.014, re-
spectively) (Figure 2B).
RA-FLS PGC-1β protein expression shows positive
correlation with clinical parameters
Moreover, significant correlations were found between
FLS PGC-1β expression and CRP, ESR or DAS28 fromTable 3 Baseline demographic and clinical features of RA
and OA patients in the study of PGC-1β expression in FLS






Age, yrs, median (range) 55 (33 to 70) 57 (51 to 68)




78 (2 to 240) 36 (12 to 168)
ESR, mm/h, median (range) 50 (11 to 83) 18 (12 to 32)




Anti-CCP-positive, n (%) 8 (100) NA
DAS28, median (range) 4.36 (3.06 to 5.82) NA
Previous medications, n (%) NA
Corticosteroids 3 (37.5) NA
Methotrexate 4 (50) NA
Leflunomide 3 (37.5) NA
Hydroxychloroquine 2 (25) NA
Infliximab 1 (12.5) NA
Etanercept 1 (12.5) NA
FLS, fibrolast-like synoviocytes; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated
peptide antibodies; DAS28, disease activity score 28-joint assessment; n, number
of patients; RA, rheumatoid arthritis; OA, osteoarthritis; NA, not applicable.eight RA patients (CRP: r = 0.738, P = 0.037; ESR: r =
0.762, P = 0.028; DAS28: r = 0.786, P = 0.021). There
was no significant correlation between PGC-1β expres-
sion and RF, anti-CCP, 28TJC, 28SJC, PtGA, PrGA, pain
VAS or HAQ (all P >0.05).
PGC-1β knockdown attenuates proinflammatory
cytokines, MMPs and RANKL production in RA-FLS
To determine the role of PGC-1β in RA-FLS proinflam-
matory cytokine production, the proinflammation produc-
tion in PGC-1β knockdown RA-FLS was compared with
negative control (NC) infected with sh-GFP. The pro-
tein expression of PGC-1β in RA-FLS transfected with
sh-PGC-1β was hardly detected compared with NC
(Figure 3A). PGC-1β knockdown suppressed the expression
of TNF-α, IL-6, IL-8, RANKL, MMP-3 and MMP-13
relative to the NC, but not IL-1β (Figure 3B and 3C). To
explore whether this effect is mediated through inhibition
of the MAPK and NF-κB signaling pathway, MAPK and
NF-κB expression were evaluated. From these results, de-
creased expression of PGC-1β visibly suppressed the acti-
vity of ERK, p38 and NF-κB, but not JNK (Figure 3A).
PGC-1β overexpression enhances proinflammatory
cytokines, MMPs and RANKL production in RA-FLS
To determine whether PGC-1β overexpression enhanced
proinflammatory cytokines production, RA-FLS were
transfected with pcDNA3.1-PGC-1β or pcDNA3.1control.
As shown in Figure 4A, PGC-1β protein expression
was significantly overexpressed in RA-FLS transfected
with pcDNA3.1-PGC-1β compared with cells transfected
with pcDNA3.1 control. PGC-1β overexpression remark-
ably exacerbated RA-FLS-mediated inflammation, as evi-
denced by upregulating TNF-α, IL-6, IL-8, RANKL,
MMP-3 and MMP-13 expression, but not IL-1β (Figure 4B
and 4C). A detailed analysis of downstream signaling
pathways was performed to detect the levels of phosphor-
ylated MAPKs and NF-κB. The levels of ERK, p38 and
NF-κB phosphorylation increased after PGC-1β overex-
pression in RA-FLS (Figure 4A).
PGC-1β knockdown enhances apoptosis in RA-FLS
The results of Annexin V APC-A and PI FCM analyses
showed that lentivirus-mediated inhibition of PGC-1β sig-
nificantly increased early apoptosis and total apoptosis except
late apoptosis relative to the NC (early apoptosis: 7.15 ±
0.10 versus 20 ± 12.11, P = 0.026; late apoptosis: 2.85 ±
2.10 versus 5.64 ± 6.69, P = 0.110; total apoptosis: 10 ± 2.20
versus 25.30 ± 18.67, P = 0.026) in RA-FLS (Figure 5A). To
assess whether this effect was mediated through perturb-
ation of the cell cycle, cellular subpopulations at various
phases of the cell cycle were analyzed. The results showed
no significant change at different phases relative to the NC
(Figure 5B).
Figure 2 Expression of peroxisome proliferator-activated receptor-gamma coactivator-1 β (PGC-1β) is over-expressed in rheumatoid
arthritis (RA)-fibrolast-like synoviocytes (FLS). (A) Immunofluorescence staining of PGC-1β in primary cultures of FLS from osteoarthritis (OA)
and RA patients. (a, DAPI (blue); b, PGC-1β (green); c, neutral light; d, merged a, b with c. a, b, c: original magnification × 400). (B) Left panel: PGC-1β
mRNA expression in FLS from RA (n = 8) compared with that from OA (n =6) evaluated by qPCR. Right panel: PGC-1β protein level in FLS from RA
patients (n = 8) and OA controls (n = 6) was detected by western blot. The intensity for each band was densitometrically quantified and
normalized against the intensity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The data are represented by mean ± SD. *P <0.05.
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To assess whether PGC-1β indirectly or directly medi-
ates ERK, p38 and NF-κB transcription, the mRNA ex-
pression of ERK, p38 and NF-κB in PGC-1β knockdown
RA-FLS were compared with NC infected with sh-GFP.
Knockdown of PGC-1β significantly suppressed mRNA
expression of NF-κB except ERK and p38 (Figure 6A),
which suggests that PGC-1β may directly mediate NF-κB
transcription.
To experimentally validate whether PGC-1β mediated
NF-κB transcription, reporter gene assays were per-
formed. Co-transfection of pcDNA3.1-PGC-1β resulted
in an increase in NF-κB luciferase activity compared
with co-transfection of pcDNA3.1 (Figure 6B). PGC-1β
progressively increased NF-κB luciferase activity in WT
more than in MUT (Figure 6C). These results suggest
that PGC-1β directly promoted NF-κB transcription.Discussion
RA is an autoimmune systemic inflammatory disease
that causes progressive synovial inflammation resulting
in irreversible joint destruction, chronic disability and
premature mortality [10]. RA-FLS are key mediators of
cartilage and bone destruction. Activated RA-FLS play
crucial roles in determining the site where inflammation
occurs and in the subsequent maintenance of persist-
ent inflammation in the joint microenvironment [29].
They act directly on cartilage through secretion of MMPs,
cathepsins and inflammatory cytokines, and indirectly
on bone by regulating osteoclastogenesis [30,31]. There-
fore, inhibition of proinflammatory cytokine, MMP
and RANKL production in RA-FLS constitutes an im-
portant target for novel therapeutic approaches that
hinder the destruction of cartilage and bone [32]. It
has been demonstrated that NF-κB and MAPK are
Figure 3 Peroxisome proliferator-activated receptor-gamma coactivator-1 β (PGC-1β) knockdown attenuates proinflammatory
cytokines, matrix metalloproteinases (MMPs) and receptor activator of nuclear factor-kappa B ligand (RANKL) production in
rheumatoid arthritis (RA)-fibrolast-like synoviocytes (FLS). (A) After PGC-1β knockdown, the protein level of mitogen-activated protein
kinases (MAPKs) in FLS was detected by western blot. (B) After PGC-1β knockdown, the proinflammatory cytokines, MMPs and RANKL mRNA
expression in FLS was evaluated by qPCR. (C) After PGC-1β knockdown, the protein level of proinflammatory cytokines was examined by cytometric
bead array, while the level of MMP-3, MMP-13 and RANKL was detected by western blot. The data are represented by mean ± SD from three
independent experiments. *P <0.05, **P <0.01, ***P <0.001.
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ing the pathophysiological development of RA
[33,34]. Activation of NF-κB and MAPKs robustly
induce proinflammatory cytokines, MMPs and
RANKL production in RA-FLS [32,35].
PGC-1β is a transcriptional coactivator that regulates
diverse signal transduction pathways [16], and has been
reported to exert protective effects through inhibition ofNF-κB activity [17]. PGC-1α overexpression vigorously
has been shown to inhibit p38 MAPK phosphorylation
[19]. It remains unknown as to whether PGC-1β plays a
role in the regulation of RA-FLS inflammation. To the best
of our knowledge, this is the first study investigating the ef-
fects of PGC-1β on inflammation in RA. In the present
study, we found that PGC-1β was expressed in lining cells
(both macrophage-like synoviocytes and fibroblast-like
Figure 4 Peroxisome proliferator-activated receptor-gamma coactivator-1 β (PGC-1β) overexpression enhances proinflammatory
cytokines, matrix metalloproteinases (MMPs) and receptor activator of nuclear factor-kappa B ligand (RANKL) production in
rheumatoid arthritis (RA)-fibrolast-like synoviocytes (FLS). (A) After PGC-1β overexpression, the protein level of mitogen-activated protein
kinases (MAPKs) in FLS was detected by western blot. (B) After PGC-1β overexpression, the proinflammatory cytokines, MMPs and RANKL mRNA
expression in FLS was evaluated by qPCR. (C) After PGC-1β overexpression, the protein level of proinflammatory cytokines was examined by
cytometric bead array, while the level of MMP-3, MMP-13 and RANKL was detected by western blot. The data are represented by mean ± SD from
three independent experiments. *P <0.05, **P <0.01, ***P <0.001.
Zhou et al. Arthritis Research & Therapy 2014, 16:472 Page 9 of 13
http://arthritis-research.com/content/16/5/472
Figure 5 (See legend on next page.)
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Figure 5 Peroxisome proliferator-activated receptor-gamma coactivator-1 β (PGC-1β) knockdown enhances apoptosis in rheumatoid
arthritis (RA)-fibrolast-like synoviocytes (FLS). (A). Flow cytometric analysis demonstrating the effect of PGC-1β knockdown on cell apoptosis.
(B) Flow cytometric analysis demonstrating the effect of PGC-1β knockdown on cell cycle progression. The data are represented by mean ± SD
from three independent experiments. *P <0.05.
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lymphocytes and plasma cells), and PGC-1β expression in
RA synovium was significantly higher than that in OA or
Orth.A synovium. Consistently, PGC-1β expression was
more notably upregulated in RA-FLS than in OA-FLS.
We also observed significant positive correlation of RA-
FLS PGC-1β expression with clinical parameters of dis-
ease activity, including DAS28, CRP and ESR. Thus, we
postulate that elevated PGC-1β expression may be poten-
tially involved in the pathogenesis of inflammation in RA.
To further explore the effect of PGC-1β on RA-FLS-
mediated inflammation, we used lentivirus sh-RNA to
inhibit PGC-1β expression and pcDNA3.1-PGC-1β to
enhance PGC-1β expression. The results showed that
the expression of TNF-α, IL-6, IL-8, MMP-3, MMP-13
and RANKL, and the activity of ERK, p38 and NF-κB,
were clearly restrained in PGC-1β knockdown RA-FLS.
Conversely, the expression of TNF-α, IL-6, IL-8, MMP-
3, MMP-13 and RANKL, and the activity of ERK, p38Figure 6 Peroxisome proliferator-activated receptor-gamma coactivat
arthritis (RA)-fibrolast-like synoviocytes (FLS). (A). After PGC-1β overexp
by qPCR. (B) After RA-FLS transfected with a wild type-NF-κB reporter region
were measured on a spectraMax M5 reader. (C) After RA-FLS transfected with
construct (MUT), the luciferase activities were measured on a spectraMax M5
experiments. **P <0.01, ***P <0.001.and NF-κB were visibly increased in PGC-1β overex-
pression RA-FLS. Several lines of evidence have demon-
strated that inhibition of ERK, p38 and NF-κB
activation dampened TNF-α, IL-6, IL-8, MMP-3, MMP-
13 and RNAKL expression in RA-FLS [35-38]. We
therefore hypothesized that PGC-1β mediated the ex-
pression of TNF-α, IL-6, IL-8, MMP-3, MMP-13 and
RANKL through ERK, p38 and NF-κB. This is further sub-
stantiated by a study that TNF-α expression was lower in
muscle-specific PGC-1α knockout mice, and TNF-α
expression increased in muscle-specific PGC-1α overex-
pression mice compared with littermate WT mice [39].
Contrary to that study, it was reported that PGC-1β
overexpression resulted in the attenuation of macrophage-
mediated inflammation by strongly inhibiting proinflam-
matory cytokine production [20]. The role of PGC-1β
appears very diverse and the proinflammatory or anti-
inflammatory effects of PGC-1β in different disease
models require further study.or-1 β (PGC-1β) promotes NF-κB transcription in rheumatoid
ression, the mRNA expression of ERK, p38 and NF-κB in FLS was evaluated
(WT) and plasmid pcDNA3.1-PGC-1β or pcDNA3.1, the luciferase activities
plasmid pcDNA3.1-PGC-1β and WT region or a mutated-NF-κB reporter
reader. The data are represented by mean ± SD from three independent
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flammatory cytokine production without IL-1β, but the
specific mechanism remains unclear. Recently, Promsong
et al. reported that ellagic acid resulted in an increase of
IL-1β and a decrease of IL-6, IL-8 and TNF-α in oral epi-
thelial cells [40]. In addition, the wild Legionella pneumo-
phila strain has been shown to increase the levels of IL-8,
IL-6, and TNF-α but not IL-1β in human pulmonary car-
cinoma cells [41]. Therefore, self-regulation of PGC-1β-
mediated IL-6, IL-8 and TNF-α expression, but not IL-1β,
might be attributed to the difference in existing pathways
regulating IL-1β, IL-6, IL-8 and TNF-α production.
It has been established that defective apoptosis contrib-
utes to synovial hyperplasia in RA. Promoting RA-FLS
apoptosis is a new treatment strategy for RA [42]. In the
present study, we found increased early apoptosis and
total apoptosis in PGC-1β knockdown RA-FLS. However,
the cell cycle showed no significant change after PGC-1β
suppression, which may imply that PGC-1β affects RA-
FLS apoptosis through a molecular mechanism other than
the cell cycle. Previous research has indicated that ERK,
p38 and NF-κB negatively regulates RA-FLS apoptosis
[43-46]. We postulated that suppression of PGC-1β might
promote RA-FLS apoptosis through inhibition of ERK,
p38 and NF-κB activation.
Our results also showed that PGC-1β downregulation
significantly inhibited the mRNA expression of NF-κB,
except for ERK and p38, which indicates that PGC-1β
might mediate NF-κB transcription. To further validate
PGC-1β-mediated NF-κB transcription, we performed
reporter gene assays. The assays showed that PGC-1β
overexpression resulted in increased NF-κB luciferase
activity, which indicated that PGC-1β directly promoted
NF-κB transcription. The result was consistent with a
previous study showing that PGC-1 downregulation de-
creases NF-κB transcription [47]. The precise mechan-
ism for the interaction between PGC-1β and ERK or p38
remains unclear and requires further study.
Conclusions
The results of this study show that suppression of PGC-1β
attenuates the expression of TNF-α, IL-6, IL-8, MMP-3,
MMP-13 and RANKL, and enhances apoptosis through
inhibition of p38, ERK and NF-κB activation in RA-FLS,
which suggests that blocking PGC-1β expression may pro-
vide a novel target for the treatment of RA.
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